KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables - Other: 2020

Historic Receivables - Other for AbCellera Biologics (ABCL) over the last 1 years, with Dec 2020 value amounting to $212.3 million.

  • AbCellera Biologics' Receivables - Other was N/A to $62.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $62.1 million, marking a year-over-year change of. This contributed to the annual value of $212.3 million for FY2020, which is N/A change from last year.
  • According to the latest figures from FY2020, AbCellera Biologics' Receivables - Other is $212.3 million.
  • AbCellera Biologics' Receivables - Other's 5-year high stood at $212.3 million during FY2020, with a 5-year trough of $212.3 million in FY2020.
  • Moreover, its 1-year median value for Receivables - Other was $212.3 million (2020), whereas its average is $212.3 million.